VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company reports is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This breakthrough addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA. By creating highly enriched tumor DNA datasets, the technology could significantly enhance cancer detection and monitoring capabilities.
According to the company, the publication describes a two-step process that combines physical sample enrichment with bioinformatic filtering to produce sequencing datasets with greater than 99% purity of ctDNA. Early validation studies have demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have also produced encouraging findings, suggesting the technology's potential clinical utility.
Volition is now advancing larger validation studies, collaborating with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities. The company is currently conducting technical evaluations with potential licensing partners and estimates that the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.
This publication marks a significant milestone for Volition, which is focused on advancing the science of epigenetics to save lives and improve outcomes through earlier detection and monitoring of life-altering diseases. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S., and an office in London. Volition is developing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including certain cancers and diseases associated with NETosis, such as sepsis.
The implications of this technology are profound. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, enabling earlier detection and real-time monitoring of cancer. The ability to isolate ultra-pure ctDNA could lead to more accurate and sensitive tests, potentially improving patient outcomes by catching cancers earlier and monitoring treatment response more effectively. As Volition continues to validate and commercialize this technology, it could become a cornerstone in the evolving landscape of precision oncology.
For more information, visit the company's website at https://volition.com/. To view the full press release, visit https://ibn.fm/nuJEs.
